Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 May 25;61(5):2201585.
doi: 10.1183/13993003.01585-2022. Print 2023 May.

The causal relationship between gastro-oesophageal reflux disease and idiopathic pulmonary fibrosis: a bidirectional two-sample Mendelian randomisation study

Carl J Reynolds  1 , Fabiola Del Greco M  2 , Richard J Allen  3   4 , Carlos Flores  5   6   7   8 , R Gisli Jenkins  9 , Toby M Maher  9   10 , Philip L Molyneaux  9 , Imre Noth  11 , Justin M Oldham  12 , Louise V Wain  3   4 , Jiyuan An  13 , Jue-Sheng Ong  14 , Stuart MacGregor  14 , Tom A Yates  15 , Paul Cullinan  9 , Cosetta Minelli  9
Affiliations
Meta-Analysis

The causal relationship between gastro-oesophageal reflux disease and idiopathic pulmonary fibrosis: a bidirectional two-sample Mendelian randomisation study

Carl J Reynolds et al. Eur Respir J. .

Abstract

Background: Gastro-oesophageal reflux disease (GORD) is associated with idiopathic pulmonary fibrosis (IPF) in observational studies. It is not known if this association arises because GORD causes IPF or because IPF causes GORD, or because of confounding by factors, such as smoking, associated with both GORD and IPF. We used bidirectional Mendelian randomisation (MR), where genetic variants are used as instrumental variables to address issues of confounding and reverse causation, to examine how, if at all, GORD and IPF are causally related.

Methods: A bidirectional two-sample MR was performed to estimate the causal effect of GORD on IPF risk and of IPF on GORD risk, using genetic data from the largest GORD (78 707 cases and 288 734 controls) and IPF (4125 cases and 20 464 controls) genome-wide association meta-analyses currently available.

Results: GORD increased the risk of IPF, with an OR of 1.6 (95% CI 1.04-2.49; p=0.032). There was no evidence of a causal effect of IPF on the risk of GORD, with an OR of 0.999 (95% CI 0.997-1.000; p=0.245).

Conclusions: We found that GORD increases the risk of IPF, but found no evidence that IPF increases the risk of GORD. GORD should be considered in future studies of IPF risk and interest in it as a potential therapeutic target should be renewed. The mechanisms underlying the effect of GORD on IPF should also be investigated.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: R.G. Jenkins reports grants from AstraZeneca, Biogen, Galecto, GlaxoSmithKline, RedX, Pliant and Genetech, consulting fees from Bristol-Myers Squibb, Daewoong, Veracyte, Resolution Therapeutics, RedX, Pliant and Chiesi, and advisory board participation with Boehringer Ingelheim, Galapagos, Vicore and Roche, outside the submitted work, and has a leadership role with NuMedii, and a leadership role and is a trustee for Action for Pulmonary Fibrosis. T.M. Maher reports consulting fees from Boehringer Ingelheim, Roche/Genentech, AstraZeneca, Bayer, Blade Therapeutics, Bristol-Myers Squibb, Galapagos, Galecto, GlaxoSmithKline, IQVIA, Pliant, Respivant, Theravance and Veracyte, and lecture honoraria from Boehringer Ingelheim and Roche/Genentech, outside the submitted work. P.L. Molyneaux reports grants from AstraZeneca, consulting fees from Hoffman-La Roche, Boehringer Ingelheim, Trevi, Redex and AstraZeneca, and lecture honoraria from Boehringer Ingelheim and Hoffman-La Roche, outside the submitted work. L.V. Wain reports grants from Orion Pharma, GlaxoSmithKline, Genentech and AstraZeneca, consulting fees from Galapagos and Boehringer Ingelheim, travel support from Genentech, and advisory board participation with Galapagos, outside the submitted work; and is an Associate Editor for the European Respiratory Journal. All other authors have nothing to disclose.

Figures

FIGURE 1
FIGURE 1
Overview of our two-sample Mendelian randomisation analysis of a) gastro-oesophageal reflux disease (GORD) on idiopathic pulmonary fibrosis (IPF) risk and b) IPF on GORD risk. SNP: single nucleotide polymorphism; G–X: gene–exposure association; G–Y: gene–outcome association.
FIGURE 2
FIGURE 2
Identification of pleiotropic instruments in the Mendelian randomisation on the effect of idiopathic pulmonary fibrosis on gastro-oesophageal reflux disease. Individual variant contributions to Cochran's Q heterogeneity statistic with the 5th (dotted line) and Bonferroni corrected (0.05/19th) percentiles (dashed line) of a Chi-squared with 1 degree of freedom.
FIGURE 3
FIGURE 3
Results of the Mendelian randomisation (MR) on the effect of idiopathic pulmonary fibrosis on gastro-oesophageal reflux disease risk using different robust methods to address the issue of pleiotropy: main analysis and sensitivity analysis with five possible pleiotropic single nucleotide polymorphisms removed. IVW-FE: inverse variance weighted fixed effect; IVW-RE: inverse variance weighted random effect; WMe: weighted median; Egger: MR-Egger; WMo: weighted mode-based.
See this image and copyright information in PMC

Comment in

References

    1. Raghu G, Remy-Jardin M, Myers JL, et al. . Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2018; 198: e44–e68. doi:10.1164/rccm.201807-1255ST - DOI - PubMed
    1. Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med 2018; 378: 1811–1823. doi:10.1056/NEJMra1705751 - DOI - PubMed
    1. Hubbard R, Johnston I, Britton J. Survival in patients with cryptogenic fibrosing alveolitis: a population-based cohort study. Chest 1998; 113: 396–400. doi:10.1378/chest.113.2.396 - DOI - PubMed
    1. Vancheri C, Failla M, Crimi N, et al. . Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J 2010; 35: 496–504. doi:10.1183/09031936.00077309 - DOI - PubMed
    1. Pardo A, Selman M. The interplay of the genetic architecture, aging, and environmental factors in the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2021; 64: 163–172. doi:10.1165/rcmb.2020-0373PS - DOI - PubMed

Publication types

MeSH terms